This Advisory outlines how healthcare providers (i.e., obstetrician-gynecologists [OB-GYNs], primary care physicians, and other professionals who treat pregnant people) can take an active role in supporting the health of pregnant individuals who have OUD and their babies.
Solr Mobile Search
Page Title
Publications and Digital Products
User account menu
Your browser is not supported
Switch to Chrome, Edge, Firefox or Safari
988 Separation Alert
Looking for 988 materials? Visit the new 988 ordering website.
Filters
Publication Category
Publication Primary Audience
Issues, Conditions and Disorders
Treatment, Prevention and Recovery
Professional and Research Topics
Substances
Format
Audience
Population Group
Series
Language
Dashboard: Filter Bricks
Main page content
This document accompanies the Clinical Guidance for Treating Pregnant and Parenting Women with Opioid Use Disorder and Their Infants publication. It offers information about child welfare systems and what the health care provider's role is in developing a Plan of Safe Care.
The fourth supplemental resource to SAMHSA’s Clinical Guidance for Treating Pregnant and Parenting Women with Opioid Use Disorder and Their Infants publication. This document contains information for pregnant people with a substance use disorder and preparing to deliver.
This advisory discusses the epidemiology of the mental health symptoms and conditions of Long COVID, provides evidence-based resources for the treatment of those conditions, and offers possible resources.
Community engagement is often cited as a tool to improve the health of the community and its members. This guide will review evidence related to leveraging community engagement to support the implementation and scale-up of evidence-based programs and policies.
This brochure gives an overview of the Mental Health Parity and Addiction Equity Act of 2008. It lists some of the common limits placed on mental health and substance use disorder benefits and services.
The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.
This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.
This updated workbook is a companion piece to the Anger Management Manual; it summarizes the information presented in each session of the 12-week program and provides worksheets for completing exercises.
This updated manual contains a 12-week cognitive–behavioral anger management group treatment model. The content includes specific instructions and suggested remarks for group leaders, and exercises for group members. This model will work in a variety of clinical settings, and with diverse audiences.
Displaying 1 - 10 out of 44